Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients

Ayşe Durnalı, Şengül Cangür, Fisun Ardıç Yükrük, +10

Medical Oncology

Prognostic FactorsAdult PatientsHigh-grade OsteosarcomaOncologyRadiation Oncology +2

Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups

Ayşe Durnalı, Fatma Paksoy Türköz, Fisun Ardıç Yükrük, +6

PLoS ONE

Lung Metastatic OsteosarcomaSurgical OncologyOsteosarcoma PatientsLung MetastasesTumoral Pathology +11

Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey

Alper Can, Erkan Doğan, İbrahim Vedat Bayoğlu, +13

Asian Pacific Journal of Cancer Prevention

Neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, neutrophil–platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?

Mutlu Doğan, Zeynep Tuğba Güven, Meltem Baykara, +3

Current Medical Research and Opinion

Gastric Carcinoma with Bone Marrow Metastasis: A Case Series

Ahmet Şiyar Ekinci, Öznur Bal, Tahsin Özatlı, +7

Journal of the Korean Gastric Cancer Association

Pancreatic CancerGastrointestinal OncologyMalignant DiseaseBone Marrow MetastasisMedicine +11

Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Önder Tonyalı, Uğur Çoşkun, Sinemis Yuksel, +15

The Breast

Breast OncologyMedicineBrain MetastasisPathologyBreast Cancer +6

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer

Gökhan Uçar, Yakup Ergün, Seli̇n Aktürk Esen, +5

Medicine

Kras Mutation NumberTumor HeterogeneityKras GeneKras MutationMedicine +12

Sunitinib-induced severe hypoglycemia in a diabetic patient

Ayşe Demirci, Öznur Bal, Ayşe Durnalı, +3

Journal of Oncology Pharmacy Practice

Clinical and Pathologic Features of Patients with Rare Ovarian Tumors: Multi-Center Review of 167 Patients by the Anatolian Society of Medical Oncology

Mevlüde İnanç, Arife Ulaş, Tülay Akman, +12

Asian Pacific Journal of Cancer Prevention

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Önder Tonyalı, Uğur Çoşkun, Nur Şener, +12

Journal of Cancer Research and Clinical Oncology

52-Week Trastuzumab TreatmentBreast OncologyOncologyNine-week Trastuzumab TreatmentBreast Cancer +3